ANZCTR search results

Patients with rheumatoid arthritis (RA) have a substantially reduced quality of life owing to debilitating reductions in functional capacity. One of the most effective and potent treatments for addressing these issues is with prescriptions of exercise, as recommended by the American College of Sports Medicine guidelines. Previous research has demonstrated that engagement, mastery and physical activity intention were associated with increases in physical activity in arthritis sufferers. The aim of this pilot prospective trial is to determine the effect of an all-inclusive education, exercise and psychological intervention on motivations and intentions to exercise along with physical function outcomes. Understanding each individuals intentions and then addressing them on an individualised basis by educational psychology in conjunction with an individualised exercise program may elucidate positive changes to a rheumatoid arthritis suffers motivation towards physical activity.

Nutritional supplements are routinely ingested throughout a training period to maximise exercise-based adaptations. While the mechanisms for adaptations can be varied and can include increased energy expenditure, reduced catabolism, and increased protein synthesis, the intended outcome is an increase in the intended adaptations to training. Pycnogenol, a herbal dietary supplement extracted from French maritime pine bark, is widely marketed for its antioxidant effects. Health benefits purported for Pycnogenol include improved cognitive function, endothelial function, and blood pressure regulation. However, the effect of Pycnogenol on exercise performance, or exercise-induced oxidative stress and inflammatory responses is less clear. Consumption of Pycnogenol has been shown to increase serum NAD+ levels and more recently a study demonstrated that French maritime pine bark extract reduced markers of oxidative stress 48 hours post exercise. Substantially more investigation into the influence of Pycnogenol on exercise performance is required to confirm these results, to examine the optimal timing and dose amount of this supplement, as well as to establish the physiological mechanisms that explain the increased time to exhaustion during intense endurance exercise. Therefore, we hypothesize that Pycnogenol, could be a supplement that increases endurance and with greater adaptations when consumed in addition to training. Here we propose a study designed to establish whether Pycnogenol can improve endurance in highly trained Cyclists

To evaluate the impact of a persona-based text-messaging service “Nellie” post-discharge on pain management and opioid use following surgery compared to standard care. The null hypothesis is that the use of Nellie does not reduce the use of opioids post-operatively in opioid-naïve patients undergoing surgery. The primary objective of this study is to evaluate the impact of a persona-based text-messaging service “Nellie” on the patient reported outcomes (PROMs) and opioid use after surgery compared to standard care. Patients are invited to take part in a research project to understand if SMS text messages could be helpful to them after surgery in understanding and managing their pain. This is because they maybe prescribed strong pain medication(s) to manage pain after surgery. Patients will receive SMS messages about managing pain once they have returned home from hospital. These messages can be about general pain information or to check-in with a choice for them to reply. The questions will ask about their pain after surgery their pain medication use and if any unused pain medications were returned to the local pharmacy. The messages will stop at day 30 after returning home. There will be two groups in the project; each group will be sent SMS messages at different time points. Patients will randomly be assigned to one of the two groups.

The slow build-up of two toxic proteins called amyloid and tau, are believed to be the cause of Alzheimer’s disease (AD). Recently, there have been global breakthroughs in the ability of new blood-tests to detect a toxic form of the tau protein implicated in AD pathology (pTau181). It is suggested that a blood-test targeting this protein will improve diagnostic accuracy, particularly in early-disease stages, allowing for the earlier start of treatments. To date, we have yet to determine whether providing such a test result to the treating clinicians of people attending a memory clinic influences clinician diagnostic confidence and management. We aim to address this gap for people attending a Memory Clinic where there is diagnostic uncertainty or mild cognitive impairment.

This is a retrospective multi-centre observational study that aims to determine the effect of environmental and occupational exposures on clinical phenotypes and incidences of ANCA positive renal vasculitis in Queensland.

This is first in human study of a new treatment drug, GQ1007 for patients with cancer that involves HER2-expression in solid tumors. This study aims to determine the maximum safest dose of GQ1007 that may be administered to cancer patients, firstly as a single therapy and secondly in combination with envafolimab therapy. Who is it for? You may be eligible for this study if you are an adult aged 18 or older, you have been diagnosed with any breast cancer, gastric cancer, gastroesophageal junction cancer, urothelial cancer, salivary gland carcinoma, gallbladder carcinoma, cholangiocarcinoma, or non-small cell lung cancer that involves solid tumours with HER2 gene expression. Additional heart and cognitive function tests will be conducted to determine suitability for enrolment. Study details This study will be conducted as four substudies (Parts 1-4), participants who choose to enrol in this study will only participate in one of the substudies. Participants enrolled into Parts 1 and 2 will receive subcutaneous injections (into the skin rather than a vein or muscle) of GQ1007 every 2 weeks for 2 years. Participants enrolled into Parts 3 and 4 will also receive subcutaneous injections of GQ1007 every 2 weeks for 2 years, and will also receive subcutaneous injections of envafolimab every 4 weeks for 2 years. All participants will undergo additional tests (including blood tests, echocardiograms and imaging) to assess the effect of the treatment on their cancer, and to monitor for side effects. Study participation is anticipated to be a maximum of approximately 26 months (up to 28 days for screening, up to 2 years of study treatment, and a Safety follow up Visit at 30 (+7) days after the last dose of any study treatment) plus long-term follow-up for subsequent anticancer therapy and overall survival. It is hoped this research will determine whether GQ1007 is safe and tolerable for patients with various cancer types. If GQ1007 is found to be safe, larger studies can then be conducted to determine the efficacy of this treatment which may then lead to improved quality of life and overall survival for future cancer patients. A Safety Review Committee (SRC) consisting of the Investigators and the Sponsor’s designated representatives will monitor safety throughout the study and make dose escalation decisions (including any decisions to explore intermediate, higher, or lower doses and/or alternative dosing schedules).

The purpose of this study is to determine the feasibility of conducting a longitudinal cohort study at Sir Charles Gairdner Hospital (SCGH) to assess functional outcomes of persons with above-knee amputation with different prosthesis types. Each participant will undergo one assessment which will include a functional gait assessment, completion of questionnaires to measure balance confidence and quality of life, and a balance assessment using the SMART EquiTest system. It is hypothesised that it will be feasible to conduct a longitudinal cohort study at SCGH.

The study examines patient outcomes and experiences in the use of depot buprenorphine formulation (Buvidal) in the treatment of patients with concurrent opioid dependence and chronic pain conditions using a prospective case series. Specifically the study will compare outcomes and experiences of patients before and after transfer from other opioid medications to Buvidal® treatment on the following measures: 1. Patient reported pain outcomes including measures of pain severity and pain interference using the Brief Pain Inventory (primary outcome); 2. Secondary outcomes include patient reported substance use (ATOP), general health and quality of life outcomes (PROMIS-29), adverse events, and patient satisfaction measures (TSQM), and use of other medications for pain management. These outcomes will be examined at baseline (in period before transferring to depot buprenorphine), and at 4 weekly intervals for 12 weeks following the first dose of depot buprenorphine, during which depot treatment will be continued. A prospective case series of patients treated in South East Sydney Local Health District Drug and Alcohol Services and Prince of Wales Hospital Department of Pain Management.

Nutritional supplements are routinely ingested throughout a training period to maximise exercise-based adaptations. While the mechanisms for adaptations can be varied and can include increased energy expenditure, reduced catabolism, and increased protein synthesis, the intended outcome is an increase in the intended adaptations to training. Pycnogenol, a herbal dietary supplement extracted from French maritime pine bark, is widely marketed for its antioxidant effects. Health benefits purported for Pycnogenol include improved cognitive function, endothelial function, and blood pressure regulation. However, the effect of Pycnogenol on exercise performance, or exercise-induced oxidative stress and inflammatory responses is less clear. Consumption of Pycnogenol has been shown to increase serum NAD+ levels and more recently a study demonstrated that French maritime pine bark extract reduced markers of oxidative stress 48 hours post exercise. Substantially more investigation into the influence of Pycnogenol on exercise performance is required to confirm these results, to examine the optimal timing and dose amount of this supplement, as well as to establish the physiological mechanisms that explain the increased time to exhaustion during intense endurance exercise. Therefore, we hypothesize that Pycnogenol, could be a supplement that increases endurance and with greater adaptations when consumed in addition to training. Here we propose a study designed to establish whether Pycnogenol can improve endurance in highly trained CrossFitters.

The KODY research is a three-year quasi-experimental study to trial a service response to the problem of domestic and family violence (DFV) where men using violence are also using alcohol or other drugs (AOD). The aims are to evaluate the effectiveness of the KODY program in supporting safety for mothers and children from DFV and other AOD-related harms, to deepen understanding of the combined impact of DFV and AOD, and identify the implications for service responses. The KODY program brings together a groupwork program for fathers who use violence (Caring Dads), incorporating specialist AOD content, with case coordination between Caring Dads and AOD practitioners, support for mothers and children, and with a linked intervention for all family members (children, mothers and fathers), including parenting education and support and recreational and therapeutic groups for children and their families.